BioLife Solutions CTO Sean Werner Sells Shares
Sean Werner, CTO of BioLife Solutions, sold shares worth $10,936.80.
Key Points
- Sean Werner, CTO of BioLife Solutions, sold 420 shares at $26.04 each on June 18, 2026, totaling $10,936.80.
- Shares of BioLife Solutions traded near $26.04 on Tuesday, with a market cap of $1.22 billion and a forward P/E of 85.9.
- Institutional investors like T. Rowe Price and Vanguard Capital Management showed interest, with notable changes in their holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Sean Werner, the Chief Technology Officer of BioLife Solutions, Inc. (NasdaqCM: BLFS), sold 420 shares of the company. The shares were sold at a price of $26.04 each, amounting to a total transaction value of $10,936.80. This sale was not part of a pre-planned trading program.
Insider Buying and Selling at BioLife Solutions, Inc.
Several insiders at BioLife Solutions, including Chief Marketing Officer Todd Berard and Chief Financial Officer Troy Wichterman, also sold shares on June 18, 2026. Berard sold 470 shares, and Wichterman sold 937 shares, each at the same price of $26.04. President and CEO Roderick de Greef sold 2,775 shares, while EVP & Chief Scientific Officer Aby Mathew sold 564 shares on the same day.
BioLife Solutions, Inc. Stock Down 31.6%
Shares of BioLife Solutions traded near $26.04 on Tuesday. The company has a market capitalization of approximately $1.22 billion. Its forward P/E ratio stands at 85.9, reflecting expectations of future earnings growth. The stock's 52-week range is between $17.86 and $29.62. BioLife's 50-day moving average is $23.28, while its 200-day moving average is $23.98. The company's liquidity is strong, with a current ratio of 7.30 and a quick ratio of 5.15.
$BLFS stock price
Daily closing prices, year to date. Not investment advice.
Other Institutional Activity in BioLife Solutions
Institutional investors have been active in BioLife Solutions. T. Rowe Price Investment Management increased its holdings by 1,325,522 shares, now owning 6,506,346 shares valued at about $124.14 million. Vanguard Capital Management opened a new position with 1,917,708 shares worth approximately $36.59 million. In contrast, Invesco Ltd. reduced its stake by 1,583,659 shares, leaving it with 2,348,532 shares valued at roughly $44.81 million.
Analysts Set New Price Targets
Analysts remain optimistic about BioLife Solutions. On August 8, 2025, HC Wainwright & Co. maintained a 'buy' rating with a price target of $32. The consensus among analysts is also positive, with a mean price target of $32.3 based on 10 analyst opinions.
About BioLife Solutions
BioLife Solutions, Inc. is a healthcare company based in Bothell, Washington. It develops and sells bioproduction products and services for the cell and gene therapy industry. The company offers a range of products, including biopreservation media, human platelet lysates, and automated cell processing machines. BioLife Solutions was founded in 1987 and is led by CEO Roderick de Greef.
Bottom Line
Insider transactions at BioLife Solutions, including sales by CTO Sean Werner, provide a glimpse into the company's internal financial activities. Investors keep a close eye on such movements as they can offer insights into management's confidence in the company. However, it's important to remember that these insider sales do not necessarily indicate a negative outlook. Institutional interest and analyst ratings suggest continued confidence in BioLife Solutions' growth prospects.
Get BioLife Solutions, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BLFS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.